< Back to previous page
Researcher
Paul Declerck
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 30 Sep 2023
Projects
1 - 10 of 28
- An integrated platform for the identification, isolation and characterization of human clock antibodies.From1 Jul 2021 → TodayFunding: Department Coordination
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Anti-tau intrabodies for the treatment of Alzheimer’s diseaseFrom1 Feb 2020 → 19 Feb 2024Funding: Baekeland
- Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stage (EV-TRACE)From1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responsesFrom1 Oct 2019 → 30 Sep 2022Funding: IOF - technology validation in lab
- Development and validation of sampling and rapid assay methods for vedozilumab and ustekinumab therapeutic drug monitoringFrom1 Dec 2018 → 30 Nov 2020Funding: Foreign private sponsor - undefined
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
21 - 30 of 197
- Improved Potency and Safety of DNA-Encoded Antibody Therapeutics Through Plasmid Backbone and Expression Cassette Engineering(2021)
Authors: Giles Vermeire, Nick Geukens, Paul Declerck, Kevin Hollevoet
Pages: 1200 - 1209 - Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis(2021)
Authors: Ruben Faelens, Zhigang Wang, Paul Declerck, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
- DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration(2021)
Authors: Giles Vermeire, Nick Geukens, Paul Declerck, Kevin Hollevoet
Pages: 828 - 838 - S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism(2021)
Authors: Paul Declerck
Pages: 81 - 87 - Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations(2021)
Authors: Nathalie Van den Berghe, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Paul Declerck, Debby Thomas
Pages: 988 - 993 - Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians(2021)
Authors: Liese Barbier, Yannick Vandenplas, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review(2021)
Authors: Paul Declerck
- A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?(2021)
Authors: Paul Declerck
- Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484(2021)
Authors: Machteld Sillen, Sergei Strelkov, Paul Declerck
- Structural analysis of antibody-based and small molecule profibrinolytics(2021)
Authors: Machteld Sillen, Paul Declerck, Sergei Strelkov
Patents
1 - 1 of 1
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1